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Abstract 
Aims: In order for Chlamydia pneumoniae to play a causative role in chronic human disease, it 
would need to persist within infected tissue for extended periods of time. Current theory 
suggests that C. pneumoniae may persist at the site of infection via an alternative replicative 
form, known as an aberrant body (AB).  
Methods: A panel of C. pneumoniae-specific antibodies up-regulated by the AB was used to 
probe tissue specimens from the coronary atheroma from 13 explanted hearts to identify patterns 
of reactivity in these tissues, as well as to determine the presence and prevalence of C. 
pneumoniae AB.  
Results: Six of 13 patients had an ischemic cardiomyopathy secondary to coronary 
atherosclerosis, while another six patients suffered from an idiopathic, dilated cardiomyopathy. 
One additional patient, a young (24 years) woman with cardiomyopathy, had no history of 
atherosclerotic disease. Eleven patients were positive by immunohistochemistry (IHC) with at 
least one antibody. Coronary arteries of the two other patients were negative by IHC with all 
antibodies.  One of these patients was the 24 year-old woman with Grade I disease and no risk 
factors for coronary artery disease.  
Conclusions: The protein antigens of persistent C. pneumoniae infection found in the 
atheromatous lesions from patients in this study could potentially be used as markers to detect 
such infections and some may be virulence factors or immunogens specific to C. pneumoniae, 
thus serving as target molecules for diagnostic use or therapeutic intervention. 
 
Keywords: Chlamydia pneumoniae, coronary atheroma, heart transplantation, persistence 
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This paper describes a detailed, prospective investigation on the prevalence and expression of a 
panel of chlamydial proteins in coronary artery tissue specimens of 13 human heart 
transplantation patients. Immunohistochemistry examinations were complemented by a 
thourough investigation of coronary artery tissue specimens by histopathology, culture, PCR 
and IMG. The specificity and suitability of the antibodies for immunohistochemistry was shown 
in previous studies (Borel et al., 2006 & 2008). Patient sera were investigated by MIF and 
Western blot with the idea to find a correlation between direct antigen or DNA detection and 
antibody reaction. The aim of this study was to find markers to detect and diagnose persistent 
chlamydial infections in patients with atherosclerosis. A panel of C. pneumoniae-specific 
antibodies up-regulated by the aberrant body was suitable to detect such infections and could 
serve as diagnostic markers in the future. 
 
 
1. Introduction 
Chlamydia pneumoniae is an obligate intracellular pathogen which causes acute and chronic 
respiratory infections in humans (1-4). Over the last decade, a significant amount of data have 
suggested a role for C. pneumoniae in chronic human disease, in particular, atherosclerosis; 
however, a direct causal role remains to be established (5).  In order for C. pneumoniae to play a 
causative role in chronic human disease, it would need to persist within infected tissue for 
extended periods of time. One hypothesis suggests that C. pneumoniae persists at the site of 
infection via an alternative replicative form, known as an aberrant body (AB) defined as viable 
but noncultivable form of chlamydiae (6).  These ABs may represent the mechanism by which 
this organism persists and causes the chronic inflammatory-type infections characteristic of C. 
pneumoniae, and other chlamydiae.  In vitro, alterations of the normal developmental cycle of 
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C. pneumoniae can be induced (7).  Although these in vitro models of persistence have been 
characterized in detail, convincing evidence for the in vivo existence and prevalence of C. 
pneumoniae AB is lacking.  Demonstration of a high prevalence of ABs in chronically-infected 
human tissue would establish this form of C. pneumoniae as a likely participant in the 
pathogenesis of disease. 
 
Chlamydial ABs have been shown to exist, in vitro (7), and we have detected AB-like structures 
of C. suis  in infected pigs (8).  We have also identified evidence of persistent C. pneumoniae in 
the atheroma of patients with coronary artery disease (CAD) by TissueMicroarray and 
Immunogoldelectron (IMG) microscopy (9,10), however, these data were collected on archived 
specimens. Therefore, we conducted a prospective examination of human atheromatous tissue 
from explanted hearts of patients receiving heart transplants.  
 
The objective of this study was to use a panel of C. pneumoniae-specific antibodies, the 
majority of which are reactive to antigens upregulated in the persistent state of the organism, to 
probe tissue specimens from the coronary arteries from explanted hearts to identify patterns of 
reactivity in these tissues, as well as to determine the presence and prevalence of C. pneumoniae 
ABs.  Antibodies directed against chlamydial proteins upregulated during the persistent stage in 
vitro (LPS/MOMP, GroEL and GroES) and suitable to screen atheromatous samples in vivo 
(9,10) were applied in the present study. In addition, recently described antibodies (11,12) 
against other chlamydial proteins such as incA, cpaf and HtrA were used to investigate coronary 
artery specimens. Immunohistochemistry examinations were complemented by a thourough 
investigation of adjacent coronary artery tissue specimens by histopathology, culture, PCR and 
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immunogoldelectron microscopy. Patient sera were investigated by microimmunofluorescence 
and Western blot with the idea to find a correlation between direct antigen or DNA detection 
and antibody reaction. 
 
2. Methods 
 
2.1. Patients  
Explanted hearts from 13 patients (IDL-01 to IDL-13) seeking heart transplantation were 
investigated. This study was approved by the University of Louisville Institutional Review 
Board and the required informed consent was obtained for each patient.  Medical records from 
each patient were analyzed for: (i) demographics: sex, age at transplantation date;  (ii) past 
medical history: neoplastic disease (active or within the last year), congestive heart failure, 
cerebrovascular disease, renal disease/chronic renal failure, liver disease/cirrhosis, neurologic 
diseases/mental illness, history of community-acquired pneumonia (CAP), chronic obstructive 
pulmonary disease (COPD); (iii) selected laboratory findings: homocysteine levels, C-reactive 
protein; (iv) established risk factors for atherosclerosis and cardiovascular events: family history 
of coronary artery disease (CAD), active CAD, essential arterial hypertension, hyperlipidemia, 
prior myocardial infarction, prior angioplasty/bypass surgery/peacemakers, atrial fibrillation, 
history of smoking, history of alcoholism, diabetes; (v) prior cardiovascular medications: 
aspirin, beta-blockers, ACE inhibitors, anticoagulants (heparin, warfarin), antiplatelets other 
than aspirin, statins, and (vi) antibiotic treatment received within the 30 days prior to 
transplantation. The age range of 12 patients at transplantation date was 47.1 and 70.2.   A 
single patient was 24 years old. There were two female and eleven male patients. In total, eight 
patients (IDL-01, IDL-04, IDL-06, IDL-07, IDL-08, IDL-09, IDL-10, IDL-12) were on left 
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ventricular assistant device (LVAD).  Of these, five patients (IDL-01, IDL-06, IDL-07, IDL-08, 
IDL-09) had recurrent drive line infections and were treated with antibiotics within 30 days 
prior to transplant. Pseudomonas aeruginosa was detected in IDL-08 and Methicillin-resistant 
Staphylococcus aureus (MRSA) in IDL-09.  For the three other patients, neither the 
organism(s), nor the antibiotics used for treatment, was recorded. Aminoglycosides, 
fluorquinolones, rifamycins, tetrazyclines and linezolid was used for antibiotic treatment in 
these two patients. 
Prior antibiotic treatment was recorded in five patients (IDL-01, IDL-06, IDL-07, IDL-08, IDL-
09). Antibiotic treatment was needed due to line infections of left ventricular assistant devices in 
all five patients. 
 
 
2.2. Histopathology  
At least two pieces of the left and right coronary arteries were collected from the excised tissue 
samples and immediately fixed in 4% buffered formalin.  Each was routinely processed and 
stained with hematoxylin and eosin.  Atheroma grading was performed by a cardiac pathologist  
and was assigned a Grade I through V occlusion score.  
 
2.3. Antibodies  
Antibodies directed against C. pneumoniae-specific proteins are shown in Table 1.  All 
formalin-fixed, paraffin-embedded coronary artery specimens were screened by 
immunohistochemistry with each antibody.  Based on the immunohistochemistry results, and 
results obtained in previous studies (9,10), the Chlamydiaceae-family specific antibody directed 
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against the LPS and MOMP (LPS/MOMP antibody; Cygnus Technologies, Inc., Southport, NC) 
was selected for immunogold electron microscopy labeling. 
 
2.4. Immunohistochemistry (IHC)  
Formalin-fixed, paraffin-embedded sections were stained with the panel of primary anti-
chlamydial-antibodies as in Table 1 and detection was performed with the Detection Kit (Dako 
ChemMateTM Detection Kit, Glostrup, Denmark) according to the manufacturer's instructions. 
The optimal dilution for each antibody was previously determined on HEp-2 cell monolayers 
infected with C. pneumoniae for 72 hrs. 
 
Antigen retrieval was performed by 20 minutes pressure cooking with HIER target retrieval 
solution (pH 6,0; Target Retrieval Solution (x 10), Dako ChemMateTM, Glostrup, Denmark) for 
all antibodies. For inhibition of the endogenous peroxidase activity, the slides were immersed in 
peroxidase-blocking solution (Dako ChemMateTM, Glostrup, Denmark) for 5 min at room 
temperature (RT). Two additional blocking solutions were added to the slides, which were 
incubated with the polyclonal antibodies GroEL and GroES: Dako Protein Block Serum-free for 
5 min at room temperature (Dako ChemMateTM, Glostrup, Denmark) and 20 min Avidin D 
solution followed by 20 min Biotin solution at room temperature (Vector Laboratories Inc., 
Burlingame, CA). The slides were then incubated with the primary antibody for 60 min 
(LPS/MOMP, incA, cpaf, HtrA) or over night (GroEL, GroES) at room temperature in a moist 
chamber. Following that, the sections were incubated for 20 min at RT with the link-antibody, 
developed in 3-amino, 9-ethyl-carbazole (AEC) substrate solution for 10 min at RT, and 
counterstained with hematoxylin. By using the antibody diluent instead of the primary antibody 
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a negative control of each section was performed. Positive controls consisted of HEp-2 cells 
infected with C. pneumoniae for 72 hrs. Patients with at least one positive localization per 
antibody were defined as positive. 
 
2.5. Transmission electron microscopy (TEM) 
Glutaraldehyde-fixed coronary artery specimens were post-fixed in osmium tetroxide and then 
embedded in epon. Appropriate areas for ultrastructural investigation were selected using semi-
thin sections (1 µm) stained with toluidine blue (Fluka, Buchs SG, Switzerland).  Ultra-thin 
sections (80 nm) for TEM were mounted on gold grids (Merck Eurolab AG, Dietlikon, 
Switzerland), contrasted with uranyl acetate dihydrate (Fluka) and lead citrate (lead nitrate and 
tri-natrium dihydrate; Merck Eurolab AG) and examined for the presence of chlamydial 
developmental stages in an electron microscope (Philips CM10).   
 
2.6. Immunogold electron microscopy labeling (IMG)  
For IMG labeling, sections were labeled with the primary antibody LPS/MOMP at a dilution of 
1:500 at RT overnight. After washing with PBS/TBS buffer for 30 min, samples were incubated 
with a 18-nm colloidal gold-conjugated polyclonal IgG anti-rabbit secondary antibody (dilution 
1:15) for 2 h. The sections were then washed for another 20 min, rinsed with deionized water, 
and contrasted as described (10).  Uninfected and infected (72h) HEp-2 cell pellets were used as 
negative and positive controls, respectively. 
 
2.7. Culture  
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Culture was performed at two laboratories in HEp-2 cell monolayers using standard methods.  
In brief, patient samples were mechanically disrupted and centrifuged at 1,000 x g onto sub-
confluent HEp-2 cell monolayers for 1h in serum free MEM-Eagles medium (Invitrogen, 
Carlsbad, CA, USA) in 24 well plates.  Subsequently, MEM-eagles, containing 10% FBS and 2 
! g/ml cycloheximide, was added.   Following 72 h of incubation at 37°C, the entire contents of 
each well was harvested and sonicated for 5 min at 4°C.  This was divided into two wells of a 
24-well plate and inoculation was carried out as described above.  Immunofluorescence 
microscopy was carried out on the contents of one well using the Pathfinder Chlamydia Culture 
Confirmation System (BioRad, Hercules, CA, USA).  The remaining well was passaged into 
two new wells after 72h of additional incubation.  
 
2.8. DNA extraction and Polymerase chain reaction (PCR) 
PCR was as performed at two separate laboratories. Prior to PCR, tissue specimens from 
coronary atheroma in M4 transport medium were processed for DNA extraction using a 
commercial DNA extraction kit (DNeasy Tissue kit; Qiag n, Hilden, Germany).  
At one site, a real-time PCR was conducted on an ABI 7500 instrument (Applied Biosystems, 
Foster City, CA) using a modified version of the procedure of Everett et al (13). This 23S-based 
Chlamydiaceae family-specific real-time PCR as described previously (14) includes primers 
Ch23S-F (5’-CTGAAACCAGTAGCTTATAAG CGGT-3’), Ch23S-R (5’-
ACCTCGCCGTTTAACTTAACTCC-3’), and probe Ch23S-p (FAM-CTCATCA 
TGCAAAAGGCACGCCG-TAMRA) and yields a 111-bp product specific for members of the 
family Chlamydiaceae. In each reaction, 2.5 l of extracted DNA was added to a mix of 
reagents containing 12.5 µl of 2X TaqMan Fast Universal PCR Master Mix (Applied 
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Biosystems, Darmstadt, Germany), with final concentration of 5pmol/l of each primer and the 
probe (Microsynth, Balgach, Switzerland) to yield a final volume of 25 l. The cycling profile 
included initial denaturation (95°C, 10 min) followed by 45 cycles of denaturation at 94°C for 
15 s, 60°C for 60 s. A cycle threshold (Ct value) of  38.00 was considered as positive, and all 
samples were tested at least in duplicate.  
At the second site, a real-time multiplex PCR with 3 probes that can detect C. trachomatis, C. 
pneumoniae and C. psittaci was used (15). 
 
2.9. Microimmunofluorescence (MIF) 
Serum samples were collected immediately prior to heart transplantation from all patients. 
Blood samples were centrifuged (3000 × g, 10 min) and sera were stored at -80 C prior to 
testing.   IgG and IgM antibody titers were determined by MIF using commercial kits (Focus 
Diagnostics, Cypress, CA) according to manufacturer's instructions. 
 
2.10. Western Blot 
In a previous study (16), the serological response to novel C. pneumoniae antigens associated 
with persistent C. pneumoniae infections was characterized. According to these results, the 
molecular chaperone Hsp70 (DnaK), the RNA polymerase -chain (RpoA) and the hypothetical 
protein CpB0704 were found to be immunodominant and thus selected to test human sera from 
the 13 transplanted patients. Serum reactivity towards RpoA, DnaK and the hypothetical protein 
CpB0704 was analyzed as described previously (17).  In brief, the recombinant proteins were 
separately applied to sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by 
electroblotting onto Bio Trace NT nitrocellulose membranes (Pall, Port Washington, NY, USA). 
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The membranes were blocked using 5% nonfat dry milk, cut into strips with 4 mm width of 
which each was incubated with a serum sample of the 13 donors at a dilution of 1:1,000. After 
four subsequent washing steps, the strips were incubated with a peroxidase-conjugated rabbit 
anti-human IgG antibody (1:2,000 dilution, DakoCytomation) for 45 min followed by another 
four washing steps. Immunoreactive bands were visualized and quantified by enhanced 
chemiluminescence detection using a LAS-3000 imaging system (Fuji) and the AIDA software 
package (Raytest/Fuji). An intensity threshold of 1,000 counts above the background level was 
used as the cutoff. 
 
3. Results 
Detailed results of individual patients are shown in Table 2. Six of 13 patients had an ischemic 
cardiomyopathy secondary to coronary atherosclerosis (IDL-01, IDL-02, IDL-06, IDL-07, IDL-
10, IDL-11) while another six patients suffered from an idiopathic, dilated cardiomyopathy 
(IDL-04, IDL-05, IDL-08, IDL-09, IDL-12, IDL-13). One patient, a young (24 y.o.) woman 
(IDL-03), had no history of atherosclerotic disease. All patients were free of neoplastic disease 
(active or within the last year prior to transplantation), cerebrovascular disease (i.e. previous 
stroke), renal diseases other than chronic renal failure, neurologic diseases/mental illness and 
liver disease/cirrhosis. In contrast, all patients (n=13) suffered from congestive heart failure and 
nine out of 13 patients had chronic renal failure. Three patients had a previous history of 
community-acquired pneumonia (IDL-06, IDL-07, IDL-08) and five patients had chronic 
obstructive pulmonary disease (IDL-5, IDL-06, IDL-08, IDL-12, IDL-13), respective y. Several 
patients had risk factors for cardiovascular events, including: family history of CAD (n=8), 
active CAD (n=11), hyperlipidemia (n=11), arterial hypertension (n=10), prior myocardial 
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infarction (n=10), history of smoking (n=10), diabetes (n=9), atrial fibrillation (n=7), or history 
of alcoholism (n=1). Prior cardiac surgery was performed in five patients (IDL-02, IDL-06, 
IDL-07, IDL-10, IDL-11). 
Homocysteine levels were elevated in eleven patients (ranged from 4.4 to 23.5 uMol/l, mean 
value was 14.4 uMol/l) and not determined in two patients (IDL-01, IDL-12). C-reactive protein 
was high in a single patient (12.1 mg/dl, patient IDL-07), but not tested in all other patients. 
Cardiovascular medications received within 30 days prior to transplantation included: aspirin 
(n=8), beta-blockers (n=12), ACE inhibitors (n=7), anticoagulant (n=11), antiplatelet (n=6) and 
statins (n=8). Prior antibiotic treatment was recorded in five patients (IDL-01, IDL-06, IDL-07, 
IDL-08, IDL-09). Antibiotic treatment was needed due to line infections of LVADs in all five 
patients. Results regarding chlamydial infections were not different between patients with line 
infections and antibiotic treatment and patients with non-infected LVAD or without LVAD. 
All 13 patients exhibited atherosclerotic lesions in their coronary arteries (Grade I to V).  One 
patient (IDL-03) had minimal atherosclerotic lesions (Grade I). Four patients had between 
Grade II and III (40-70% occlusion), six patients showed Grade IV lesions (80-95% occlusion) 
and Grade V (100% occlusion) was seen in two patients. 
Representative positive immunohistochemistry labeling with the antibodies LPS/MOMP, 
GroES, incA and HtrA on patient coronary specimens, in comparison with infected HEp-2 cell 
pellets, is shown in Figure 1. Coronary arteries of two patients were negative by IHC with all 
antibodies (IDL-03, IDL-09).  One of these patients was the 24 year-old woman (IDL-03) with 
Grade I disease and no risk factors for CAD.  All other eleven patients were positive by 
immunohistochemistry with at least one antibody. Likewise, all eleven patients showed positive 
reactions in at least one tissue specimen with the LPS/MOMP antibodies, ten patients were 
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positive by the GroEL antibody and nine patients revealed positive labeling with the GroES, 
incA and HtrA antibodies. Only three patients were positive with the cpaf antibody. 
A rigorous examination of a minimum of four grids for each tissue specimen, for a total of 52 
grids, by TEM and IMG using the LPS/MOMP antibody failed to detect the presence of any 
normal (elementary, intermediate and reticulate bodies) or altered replicative state of C. 
pneumoniae, including AB (data not shown).  
 Culture and PCR for C. pneumoniae was negative in all 13 patients in both laboratories (data 
not shown). 
All 13 patient sera were negative for IgM antibodies by MIF (data not shown). IgG titers were 
lower (n=2) or equal (n=2) to 1:64, or higher: 1:128 (n=1), 1:256 (n=7) and highest in patient 
IDL-08 (1:512).  Western blot analysis of sera showed positive results for RpoA (n=3), DnaK 
(n=2) or both (n=6). Only three sera showed reactivity to the hypothetical protein CpB0704. 
 
4. Discussion 
Atheromatous tissues from patients with Grade III to V pathology demonstrated reactivity to 
antibodies to C. pneumoniae proteins that are upregulated in models of in vitro persistence. One 
young patient, who could conceivably be viewed as a "negative control" in this study, showed 
no reactivity to any of the serum antibodies tested. This patient was transplanted due to 
cardiomyopathy at a very young age and also had no risk factors for CAD.  Eleven of the 12 
other patients showed a variable degree of reactivity with one or more of the antibodies tested, 
indicating the presence of these antigens within the atherosclerotic lesions of these patients. 
These chlamydial antigens could be responsible for triggering inflammatory responses via 
receptor-dependent manner in the absence of replicating chlamydial organisms. Furthermore, 
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ongoing inflammatory and necrotic processes in chronically-infected atherosclerotic lesions can 
co-stimulate pattern recognition receptors by danger-associated molecular patterns. Though, in 
the light of negative culture results in all 13 patients, it is possible that C. pneumoniae antigens 
persisted in chronically-infected coronary atheroma in the absence of normal replication. The 
persistence of C. pneumoniae antigens rather than viable bacteria has been reported in the 
literature in vitro and in vivo (18,19). As observed in our study, Meijer et al. (19) found a 
granular staining patt rn for MOMP, hsp60 and LPS in infected mice by IHC instead of visible 
inclusions. The granular staining pattern of antigens in the absence of staining for DNA by in 
situ hybridization was caused by non-viable bacteria as stated by the authors and these findings 
are in accordance with negative PCR and culture results but positive labeling for different 
chlamydial proteins in the majority of the heart transplantation patients. Furthermore, rapid 
degradation of DNA in atherosclerotic lesions but persistence of LPS and MOMP in the vessel 
walls as reported by Meijer et al. (18) could support our results.  
 
By immunohistochemistry, antibodies against chlamydial proteins whose increased expression 
has been demonstrated in in vitro models of persistence (7), were applied to detect persistent 
infections. Antibodies against LPS/MOMP, GroEL and GroES were suitable to detect aberrant 
bodies of C. pneumoniae by IHC and IMG in two previous studies on archived material (9,10) 
and similarly showed positive labeling in the majority of patients in the present study. By 
proteomic analyses, MOMP and heat shock proteins such as GroEL and GroES have been 
shown to be upregulated in various induced persistence models of C. pneumoniae (20,21) and 
these findings were confirmed by our study of coronary artery samples. 
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The chlamydial protease-like activity factor (cpaf) is a major factor of chlamydial pathogenicity, 
Chlamydia-associated cell damage and inflammation (22) and has different localizations in the 
cell depending on acute or persistent C. pneumoniae infection (23). Antibodies to cpaf have 
been detected in women with C. trachomatis cervicitis (24) and may promote C. trachomatis 
persistence (25). In addition, the highest increase in serum reactivity in C. pneumoniae-positive 
donors was found towards cpaf in a recent study (16) implicating cpaf as a persistence marker 
candidate. However, only three patient specimens were positive for cpaf by IHC and 
preliminary experiments by Western blot showed few positive serum samples (data not shown), 
thus cpaf seems not to be strongly expressed in C. pneumoniae persistence, in vivo.   In contrast, 
the antibody against HtrA reacted positive in nine patients comparable to the labeling with the 
LPS/MOMP, GroEL and GroES antibodies. HtrA is a virulence and stress response periplasmic 
serine protease and molecular chaperone and is up-regulated during C. trachomatis persistence 
in vitro (11,26). Chlamydial chaperone proteins such as HtrA, GroEL and GroES may be used 
as a panel marker to detect persistent C. pneumoniae infections in vivo. The regulation of the 
incA protein, an effector protein secreted by the chlamydial type III secretion system (27), under 
chlamydial persistence has not been reported so far, but positive labeling in nine out of 13 
patients indicate its possible expression during chlamydial persistence. 
 
A rigorous and labor-intensive examination by TEM and IMG failed to reveal the presence of 
any normal or altered replicative forms of C. pneumoniae, including AB.  One conclusion would 
be that there are indeed no AB to be found in any of these tissue specimens or patients, and that 
a larger group of patients would need to be examined. However, this would go against the 
theory of a relatively high prevalence of AB participating in the atherogenic response in 
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humans.  The possibility exists that AB are present and prevalent in human coronary atheroma, 
but that a more complete TEM and IMG examination is needed. By IMG, intracellular, atypical, 
round to oval structures of variable diameter resembling reticulate bodies of Chlamydia, located 
within smooth muscle cells, macrophages or fibroblasts, were described in a previous study (10) 
on atherosclerotic tissue from five patients seeking heart transplantation. The absence of typical 
chlamydial inclusions and their developmental forms (elementary and reticulate bodies) and the 
presence of necrotic c llular debris mixed with lipids and calcified material made it demanding 
to screen TEM sections and limits the screening for chlamydial structures by TEM and IMG. 
Admittedly, one ultra-thin section only reveals a very small area of the entire atheroma, leaving 
many areas of the atheroma unscreened.  A thorough investigation of the whole complete area of 
the coronary artery specimens was not possible in this study due to time and cost restraints. 
 
Selected C. pneumoniae proteins with antigenic properties, such as RpoA, DnaK and the 
hypothetical protein CpB0704 were used to test patient sera by Western Blot. Of these, highest 
increase in serum reactivity of PCR-positive donors was found toward RpoA in a previous study 
(16). This protein was reported to be the most up-regulated protein during IFN--mediated in 
vitro persistence (21). Consistent with the finding of increased expression of RpoA under 
persistence were the positive results towards this protein in nine out of 13 heart transplantation 
patients by Western Blot in our study. Corresponding immunohistochemistry results on patient 
tissue specimens were lacking due to unavailability of an antibody against the RpoA protein. 
The molecular chaperone Hsp70 (DnaK), another strongly upregulated protein under in vitro 
persistence, was one of the immunodominant proteins used for screening of patient sera 
resulting in eight positive samples. In contrast to RpoA, seroreactivity to DnaK was not 
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significanlty increased in sera of PCR-positive donors in the immunoproteomic identification 
study (16). However, results in our study were comparable for these two proteins. This could be 
explained by distinct antibody response patterns toward persistence-associated C. pneumoniae 
antigens in vivo as shown by variable presence or absence of dual IFN- - and IL-2-producing 
T-cell responses among C. pneumoniae-seropositive individuals (17). Only three patient sera 
showed reactivity to the hypothetical protein CpB0704 that was previously described to have 
unaltered seroreactivity among persistently infected patients (16). Generating antibodies against 
RpoA and DnaK for their use in IHC on atheromatous tissues is planned for comparative studies 
on tissues and serum samples. 
 
5. Conclusion 
In summary, the various antigens of persistent C. pneumoniae infection found in atheromatous 
lesions in this study could potentially be used as markers to detect such infections. Some of 
these may be virulence factors or immunogens specific to C. pneumoniae, thus serving as target 
molecules for diagnostic use or therapeutic intervention.  
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11. Figure Legends 
Figure 1.  
Comparative immunohistochemistry results of HEp-2 cells (left panel) and of patient tissue 
(right panel). Coronary artery specimens from patient number 1 (IDL-1) and patient number 4 
(IDL-4) are shown. Antibodies against the lipopolysaccharide and the major outer membrane 
protein of the family Chlamydiaceae (LPS/MOMP), the heat-shock protein GroES, the inclusion 
membrane protein incA, and the DO serine protease HtrA were used. Positive labeling with the 
respective antibodies is present intracytoplasmic in chlamydial inclusions in HEp-2 cells (left 
panel) and intracytoplasmic and granular in macrophages and smooth muscle cells of coronary 
arteries of heart transplant patients (right panel). 
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Table 1.  Antibodies used for immunohistochemistry (IHC) and immunogold labeling (IMG). 
______________________________________________________________________________________________________________ 
Antibody  Antigen   Upregulated  Type   Dilution Source  Reference 
       in persistence  
 
LPS/MOMP  Chlamydiaceae family yes   rabbit polyclonal 1:8001/1:5002 Cygnus          commercial 
GroEL   heat-shock protein  yes   rabbit polyclonal 1:200  2D Gel plug 9 
GroES   heat-shock protein  yes   rabbit polyclonal 1:400  2D Gel plug 9  
incA   Inclusion membrane  not known  mouse monoclonal 1:50  G. Zhong 12  
cpaf   protease-like activity  yes   mouse monoclonal 1:100  G. Zhong 12  
HtrA   DO serine protease  yes   rabbit polyclonal 1:400  P. Timms 11 
______________________________________________________________________________________________________________ 
1dilution for immunohistochemistry 
2dilution for immunogold labling 
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Table 2. Details of selected results in heart transplantation patients IDL-01 to IDL-13. 
 
IDL Pathology Age Sex Risk factors for atherosclerosis Immunohistochemistry Western Blot MIFa 
    1 2 3 4 5 6 7 8 9 10 LPS/ 
MOMP 
GroEL GroES incA cpaf HtrA RpoA DnaK CpB 
0704 
IgG 
01 Grd III/60% 58 m yes no yes yes no no yes yes no yes Pos Pos Pos Pos Pos Pos Neg Neg Pos 1:64 
02 Grd V/100% 58 m yes yes yes yes yes yes no no no yes Pos Pos Pos Pos Pos Neg Pos Neg Neg 1:256 
03 Grd I/10% 24 f no no no no no no yes no no no Neg Neg Neg Neg Neg Neg Neg Neg Neg 1:64 
04 Grd IV/90% 51 m no yes yes yes yes no no yes no yes Pos Pos Pos Pos Neg Neg Neg Pos Neg 1:64 
05 Grd III/40% 57 f no yes no yes no no no yes no yes Pos Pos Pos Pos Neg Pos Pos Pos Neg 1:256 
06 Grd IV/80% 62 m yes yes yes yes yes yes yes yes no yes Pos Pos Pos Pos Neg Pos Neg Pos Neg 1:256 
07 Grd IV/95% 47 m yes yes yes yes yes yes no yes no yes Pos Pos Pos Pos Neg Pos Pos Neg Neg 1:64 
08 Grd III/70% 60 m no yes no no yes no yes yes yes no Pos Pos Neg Neg Neg Pos Pos Neg Neg 1:256 
09 Grd III/50% 59 m yes yes yes yes yes no yes yes no yes Neg Neg Neg Neg Neg Neg Pos Pos Neg 1:512 
10 Grd IV/90% 70 m yes yes yes yes yes yes yes yes no yes Pos Neg Neg Pos Neg Pos Pos Pos Pos 1:128 
11 Grd IV/90% 53 m yes yes yes yes yes yes no yes no no Pos Pos Pos Neg Pos Pos Pos Pos Pos 1:256 
12 Grd IV/80% 55 m yes yes yes yes yes no yes no no no Pos Pos Pos Pos Neg Pos Pos Pos Neg 1:256 
13 Grd V/100% 60 m no yes yes yes yes no no yes no yes Pos Pos Pos Pos Neg Pos Pos Pos Neg 1:64 
 
1 family history of coronary artery disease (CAD) 
2 active CAD 
3 arterial hypertension 
4 hyperlipidemia 
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5 prior miyocardial infarction 
6 previous surgery 
7 atrial fibrillation 
8 history of smoking 
9 history of alcoholism 
10 Diabetes 
aMicroimmunofluorescence 
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